Payment overview · 2025
General Payments
$205.80
17 reported records · 4 companies
Healthcare provider profile · identity verified
Charles Patrick Gennaula, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BELLE VERNON, PA · NPI 1013914746
Verified facts
What the public records show
CMS Open Payments records show Charles Patrick Gennaula, M.D. received $205.80 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 66.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Botox by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $136.43 | 66.3% | 13 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $36.75 | 17.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.25 | 8.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.37 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $205.80 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $136.43 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.32 | 7 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $36.75 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 686 | 131 |
| Donepezil Hcl | Donepezil Hcl | 568 | 112 |
| Levetiracetam | Levetiracetam | 368 | 64 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 363 | 71 |
| Memantine Hcl | Memantine Hcl | 282 | 59 |
| Baclofen | Baclofen | 246 | 49 |
| Primidone | Primidone | 179 | 30 |
| Lamotrigine | Lamotrigine | 153 | 22 |
| Topiramate | Topiramate | 148 | 28 |
| Propranolol Hcl | Propranolol Hcl | 142 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 39 |
| Clonazepam | Clonazepam | 128 | 24 |
| Carbamazepine | Carbamazepine | 101 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 17 |
| Carbamazepine Er | Carbamazepine | 83 | suppressed |
| Pregabalin | Pregabalin | 73 | 13 |
| Divalproex Sodium | Divalproex Sodium | 70 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 67 | 11 |
| Atorvastatin Calcium | Atorvastatin Calcium | 61 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 60 | 15 |
| Lacosamide | Lacosamide | 58 | 11 |
| Sertraline Hcl | Sertraline Hcl | 57 | 17 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 57 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 55 | 12 |
| Phenobarbital | Phenobarbital | 54 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 43 | suppressed |
| Lorazepam | Lorazepam | 40 | 14 |
| Dimethyl Fumarate | Dimethyl Fumarate | 36 | suppressed |
| Prednisone | Prednisone | 35 | suppressed |
| Amantadine | Amantadine Hcl | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 27 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Zonisamide | Zonisamide | 23 | suppressed |
| Dalfampridine Er | Dalfampridine | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Azathioprine | Azathioprine | 17 | suppressed |
| Botox | Onabotulinumtoxina | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Ocrevus | Ocrelizumab | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Ampyra | Dalfampridine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Dilantin | Phenytoin | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $205.80 · 17 records | PFIZER INC. | BOTOX, ELIQUIS, KISUNLA, Leqembi, NURTEC ODT, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error